[MK Golden Cross Breakout Stocks: HYBE (352820) & Aribio Lab (261780)]
Predicted impact: Low
Aribiolab아리바이오랩
261780 · KOSDAQ · ₩261780 · 아리바이오랩
₩3,400▼ ₩185 (5.16%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y +20.14%
- Market cap
- ₩98B
- Enterprise value
- ₩83B
- P/E
- —
- P/B
- 10.0×
- Dividend yield
- 0.0%
- ROE
- −150.8%
- Net margin
- −8,616.3%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−49.4% from the high
₩1,824Today: ₩3,330 – ₩3,595₩6,720
Returns
- 1W−11.2%
- 1M−3.3%
- 3M+60.4%
- 6M−14.7%
- YTD+20.4%
- 1Y+20.1%
- Volume today
- 378,190
- 0.6× the 20-day average
- Traded today
- ₩1.3B
- Listed shares
- 28,955,976
- EPS (12 months)
- −₩515
- Earnings yield −15.2%
AI research · Update noteAribiolab: Model Fair Value Estimate Rises to ₩567 per Share, Still Far Below Market PriceThe change in the model output is large in percentage terms but comes without new financial results or a filing that explains it.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
−5.2% on Oct 27, 2026.
- • Foreign investors sold a net ₩120M that day
We found no news, filing or broker report explaining it yet. Moves without news happen; it may come later.
Possible reasons, not certainties. Not financial advice.
Signals
Quiet- BuzzQuietBuzz 34 of 100 (50 is a normal day for this stock).
- MomentumFlat-1.3% over the last month; the price is below its 20-day average.
- News impactSome3 news items and filings in two weeks; 0 rated high impact, 2 medium.
Signals describe activity, not recommendations. Not financial advice.
Aribiolab stock overview
Aribiolab (아리바이오랩, KRX: 261780) is listed on KOSDAQ, in the Biotech & Pharma sector. This company is a Korean biotech venture that develops next-generation vaccines and immunotherapies using its proprietary adjuvant platform, which includes the L-pampo and Lipo-pam adjuvants. Its shares closed at ₩3,400 on Oct 27, 2026, down 5.16% on the day, giving it a market value of ₩98B.
Key facts
- Market cap
- ₩98B
- Sector
- Biotech & Pharma
- Latest price change
- −5.16%
- As of
- Oct 27, 2026
- Main business
- This company is a Korean biotech venture that develops next-generation vaccines and immunotherapies using its proprietary adjuvant platform, which includes the L-pampo and Lipo-pam adjuvants.
Quick answers about Aribiolab
- What does Aribiolab do?
- This company is a Korean biotech venture that develops next-generation vaccines and immunotherapies using its proprietary adjuvant platform, which includes the L-pampo and Lipo-pam adjuvants. Its lead pipeline targets chronic hepatitis B therapeutic vaccines, improved preventive vaccines for hepatitis B and shingles, and cancer immunotherapies, with development extending to other infectious diseases such as influenza and norovirus. The company was founded in 2000 and is part of the CHA Biotech group in South Korea.
- What is the market cap of Aribiolab?
- The market capitalisation of Aribiolab was ₩98B at the close on Oct 27, 2026.
- Who are the largest shareholders of Aribiolab?
- According to the latest official filings, the largest reported holders are Ariabio Holdings (20.69%, as of Sep 16, 2026); Cha Biotech (5.70%, as of May 8, 2026); Ko Jeong-jae (0.26%, as of Apr 1, 2026).
- When is the next earnings report from Aribiolab?
- Korean companies rarely announce results dates in advance. Based on when Aribiolab filed the same report in past years, its next 3q results is expected around Nov 13, 2026.
Company profile
This company is a Korean biotech venture that develops next-generation vaccines and immunotherapies using its proprietary adjuvant platform, which includes the L-pampo and Lipo-pam adjuvants. Its lead pipeline targets chronic hepatitis B therapeutic vaccines, improved preventive vaccines for hepatitis B and shingles, and cancer immunotherapies, with development extending to other infectious diseases such as influenza and norovirus. The company was founded in 2000 and is part of the CHA Biotech group in South Korea.
Written by AI from the company's latest annual report.
- Korean name
- 아리바이오랩
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 정재준
- Founded
- Jun 2000
- Listed
- Oct 2021
- Listed shares
- 28,955,976
- Fiscal year ends
- Month 12
- Website
- www.chavaccine.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Recent filings
See allTitles in Korean until English translations are added.
Also known as: Aribiolab / 아리바이오랩 / 261780 / KRX:261780
Source: KRX statistical information